- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
A company based in Sunnyvale sought FDA approval for therapies and held a conference in New York City.
3 reports, 1 independent
Updated Sep 4
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A company based in Sunnyvale sought FDA approval for therapies and held a conference in New York City.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- LENZ Therapeutics is engaged with the FDA regarding LNZ100.Sub-event
Company sought FDA approval for therapies and presented at a conference in NYC.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- FDA reviewed an NDA and entered a clinical study agreement for a babesiosis trial involving 60 Degrees Pharmaceuticals.
- FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.
- FDA approved a medical device from Abbott and supported a PARADIGM study based on data from the Cleveland Clinic.
- Johnson & Johnson acquired Intra-Cellular Therapies and is seeking FDA approval for related drugs.
Coverage
Newest first; wire copies grouped- GlobeNewswireBioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025 SUNNYVALE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- - Bi
- GlobeNewswireSeres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading li
- GlobeNewswireBioCardia Reports Second Quarter 2025 Business Highlights and Financial Results SUNNYVALE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-d